Aubagne, February 18, 2021

Sartorius Stedim Biotech: Information on Document Availability

Sartorius Stedim Biotech Group's Universal Registration Document 2020 is now available at:

https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/news-financial-publications

It contains the following information:

- Business development for fiscal 2020 and the 2021 forecast for the Sartorius Stedim Biotech Group

- Consolidated financial statements for the year ended December 31, 2020

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.

Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations

Phone: +49(0)551.308.1686; [email protected]